Vancouver-based
Ketamine One Capital Limited (NEO: MEDI, Forum) is launching a single arm, open label study of patients with post-traumatic stress disorder who are undergoing the proprietary physical therapy program at the Company’s IRP Health clinics as well as an observational, single-arm, pilot study aimed at collecting objective biometric data and validated psychiatric instrument measures of efficacy in patients with depression symptoms who are receiving IV ketamine infusion therapy. The research studies will be conducted across multiple Ketamine One clinic locations in Canada and the United States and are both expected to begin next month and last 12 weeks.
In
a news release on Thursday, Ketamine One’s Interim CEO Adam Deffett called these inaugural studies a great milestone for the company, and a clear demonstration of the synergies being created between the subsidiaries of
KGK Science and
IRP Health.
“These studies represent full collaboration between all our divisions - KGK, IRP Health and our ketamine clinic network. Our mental health platform is enabling us to explore important topics and seek to find the answers to long-standing questions about the efficacy of IV ketamine treatments and how to improve treatment outcomes.”
The goal is that both the PTSD Study and the Depression Study yield significant results, which enable not only MEDI’s clinicians but those in other clinics as well as to improve the patient experience and alleviate chronic pain, depression, and other interrelated issues.
Focused on consolidating medical clinics and becoming a North American leader in mental health treatments, Ketamine One has a network of 16 clinics across North America. Earlier this month, the company’s wholly owned contract research organization,
KGK Science Inc., was contracted by a third party to develop the protocol and informed consent form to support its Institutional Review Board application. The engagement of the company by the third party is related to a ketamine clinical trial that is being planned to be conducted by a clinic operator within its medical facilities located in Miami, Florida.